Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. September 2019 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst...
05. September 2019 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the 2019 ASBMB Symposium on Serine Proteases in Pericellular Proteolysis and Signaling Conference

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the 2019 American Society for Biochemistry and...
29. August 2019 16:55 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Transition of Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that its chief financial officer, Fletcher Payne, will be stepping down from...
16. August 2019 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the 2019 Hemophilia Drug Development Summit

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the Second Annual 2019 Hemophilia Drug Development...
08. August 2019 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences to Host Key Opinion Leader Meeting on Next-Generation Subcutaneous Factor VIIa Marzeptacog Alfa (Activated) in Patients with Bleeding Disorders on August 15

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that it will host a Key Opinion Leader (KOL) meeting on next-generation...
01. August 2019 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports Second Quarter 2019 Operating & Financial Results and Provides a Corporate Update

Phase 2 trial of subcutaneously administered MarzAA met primary endpoint of reduction in annualized bleed rate demonstrating safety and clinical efficacy, with >90% reduction in bleeding DalcA...
08. Juli 2019 05:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors

Subcutaneous MarzAA (FVIIa) prophylaxis reduced the annualized bleeding rate by more than 90% compared with pretreatment Data presented at the 2019 Congress of the International Society on Thrombosis...
01. Juli 2019 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Oral and Poster Presentations at the International Society on Thrombosis and Haemostasis

Oral presentation of the final Phase 2 trial data of MarzAA for the treatment of hemophilia A or B with inhibitors Company to host investor call and webcast on Monday, July 8 at 8:00 a.m. EDT SOUTH...
28. Mai 2019 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the Jefferies 2019 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst...
02. Mai 2019 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update

Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019 MarzAA Orphan Drug Designation received from the European...

Vorherige Seite

Nächste Seite